Literature DB >> 15887971

Mono- and bis-thiazolium salts have potent antimalarial activity.

Abdallah Hamzé1, Eric Rubi, Pascal Arnal, Michel Boisbrun, Carole Carcel, Xavier Salom-Roig, Marjorie Maynadier, Sharon Wein, Henri Vial, Michèle Calas.   

Abstract

Three new series comprising 24 novel cationic choline analogues and consisting of mono- or bis (N or C-5-duplicated) thiazolium salts have been synthesized. Bis-thiazolium salts showed potent antimalarial activity (much superior to monothiazoliums). Among them, bis-thiazolium salts 12 and 13 exhibited IC(50) values of 2.25 nM and 0.65 nM, respectively, against P. falciparum in vitro. These compounds also demonstrated good in vivo activity (ED(50) </= 0.22 mg/kg), and low toxicity in mice infected by Plasmodium vinckei.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15887971     DOI: 10.1021/jm0492608

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  11 in total

1.  Symmetrical choline-derived dications display strong anti-kinetoplastid activity.

Authors:  Hasan M S Ibrahim; Mohammed I Al-Salabi; Nasser El Sabbagh; Neils B Quashie; Abdulsalam A M Alkhaldi; Roger Escale; Terry K Smith; Henri J Vial; Harry P de Koning
Journal:  J Antimicrob Chemother       Date:  2010-11-14       Impact factor: 5.790

Review 2.  Recent updates in the discovery and development of novel antimalarial drug candidates.

Authors:  John Okombo; Kelly Chibale
Journal:  Medchemcomm       Date:  2018-02-02       Impact factor: 3.597

3.  High Accumulation and In Vivo Recycling of the New Antimalarial Albitiazolium Lead to Rapid Parasite Death.

Authors:  Sharon Wein; Nicolas Taudon; Marjorie Maynadier; Christophe Tran Van Ba; Delphine Margout; Yann Bordat; Laurent Fraisse; Kai Wengelnik; Rachel Cerdan; Françoise Bressolle-Gomeni; Henri J Vial
Journal:  Antimicrob Agents Chemother       Date:  2017-07-25       Impact factor: 5.191

4.  Targeting the Lipid Metabolic Pathways for the Treatment of Malaria.

Authors:  Choukri Ben Mamoun; Sean T Prigge; Henri Vial
Journal:  Drug Dev Res       Date:  2010-02       Impact factor: 4.360

5.  Potent antihematozoan activity of novel bisthiazolium drug T16: evidence for inhibition of phosphatidylcholine metabolism in erythrocytes infected with Babesia and Plasmodium spp.

Authors:  Eric Richier; Giancarlo A Biagini; Sharon Wein; Frederic Boudou; Patrick G Bray; Steve A Ward; Eric Precigout; Michèle Calas; Jean-François Dubremetz; Henri J Vial
Journal:  Antimicrob Agents Chemother       Date:  2006-10       Impact factor: 5.191

6.  New insight into the mechanism of accumulation and intraerythrocytic compartmentation of albitiazolium, a new type of antimalarial.

Authors:  Sharon Wein; Christophe Tran Van Ba; Marjorie Maynadier; Yann Bordat; Julie Perez; Suzanne Peyrottes; Laurent Fraisse; Henri J Vial
Journal:  Antimicrob Agents Chemother       Date:  2014-07-07       Impact factor: 5.191

Review 7.  Recent highlights in antimalarial drug resistance and chemotherapy research.

Authors:  David A Fidock; Richard T Eastman; Stephen A Ward; Steven R Meshnick
Journal:  Trends Parasitol       Date:  2008-10-18

8.  Transport and pharmacodynamics of albitiazolium, an antimalarial drug candidate.

Authors:  S Wein; M Maynadier; Y Bordat; J Perez; S Maheshwari; P Bette-Bobillo; C Tran Van Ba; D Penarete-Vargas; L Fraisse; R Cerdan; H Vial
Journal:  Br J Pharmacol       Date:  2012-08       Impact factor: 8.739

Review 9.  Choline analogues in malaria chemotherapy.

Authors:  Suzanne Peyrottes; Sergio Caldarelli; Sharon Wein; Christian Périgaud; Alain Pellet; Henri Vial
Journal:  Curr Pharm Des       Date:  2012       Impact factor: 3.116

10.  A chemical proteomics approach for the search of pharmacological targets of the antimalarial clinical candidate albitiazolium in Plasmodium falciparum using photocrosslinking and click chemistry.

Authors:  Diana Marcela Penarete-Vargas; Anaïs Boisson; Serge Urbach; Hervé Chantelauze; Suzanne Peyrottes; Laurent Fraisse; Henri J Vial
Journal:  PLoS One       Date:  2014-12-03       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.